Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | PRPS1 | P60891 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5463328 | 0.90 | KCNH2 (0.53) | KCNH2HTR2AKDM4ECYP1A2CYP3A4 | |
| SCHEMBL5453388 | 0.89 | KCNH2 (0.52) | KCNH2HTR2APRPS1KDM4ECYP1A2 | |
| SCHEMBL14410968 | 0.88 | KCNH2 (0.50) | KCNH2HTR2AKDM4ECYP1A2CYP3A4 | |
| SCHEMBL14411329 | 0.86 | KCNH2 (0.57) | KCNH2HTR2ACREBBPCNR1 | |
| SCHEMBL5448736 | 0.84 | KCNH2 (0.60) | KCNH2HTR2ACREBBPCNR1 | |
| SCHEMBL14464351 | 0.83 | PRPS1 (0.47) | PRPS1CYP2D6CNR1 | |
| SCHEMBL5460659 | 0.83 | PRPS1 (0.45) | PRPS1CNR1 | |
| SCHEMBL5450136 | 0.82 | DRD2 (0.48) | PRPS1CYP2D6CNR1 | |
| SCHEMBL5447876 | 0.81 | ALDH1A1 (0.55) | KCNH2HTR2AKDM4ECYP1A2CYP3A4 | |
| SCHEMBL5450982 | 0.81 | PRPS1 (0.45) | PRPS1CREBBPCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | KCNH2 4294/4885HTR2A 396/4885PRPS1 4276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.